Rapidly progressive dementia covers many conditions, including Creutzfeldt-Jacob disease (CJD). Gregory (Gregg) Day, M.D., explains how Mayo Clinic Laboratories' new evaluations help identify the cause of rapidly progressive dementia, to guide prognosis and treatment decisions.

Show notes

Speaker 3: (00:32)
Can you provide a little background about your role here at Mayo Clinic and experience with this disease state?

Speaker 3: (01:21)
 Can you give us an understanding of rapidly progressive dementia? How is it different and what should physicians be looking for?

Speaker 3: (03:13)
 You mentioned "syndromic" and that there are several diseases underneath that, one of them being Creutzfeldt-Jacob. Can you explain the others in a bit more detail? What makes them each unique under the heading of rapidly progressive dementias?

Speaker 3: (05:29)
 Does that encompass it: prion diseases, then the neurodegenerative bucket, then autoimmune?

Speaker 3: (06:03)
 Can you speak to the components of the new Creutzfeldt-Jacob disease-specific evaluation and the rapidly progressive dementia evaluation, and the assays that they're performed on?

Speaker 3: (09:30)
 Anything you want to add to that summary of the assays' components?

Speaker 3: (11:09)
 Can you explain the role — or lack thereof — of the 14-3-3 protein biomarker, according to our research?

Speaker 3: (13:44)
 Which patients should get this testing, and who should not?

Speaker 3: (17:22)
 What does it mean if the results come back positive and if the results come back negative?

Speaker 3: (21:57)
 What are you most excited about with these tests?